I agree completely- if the OxyC trials show promising results then POH will give it more attention and funding for development- POH as Harry said would then be embarking " on a new market for this class of (pain) products".
Roberts and others have suggested that any Pharma deal will take both OxyM an OxyC as a package- might we see interest from partners on the back of these OxyC Trials for the entire Pain portfolio- fingers crossed .
License, License Licence is POHs mantra in 2014
Chart, Cash and Scenarios, page-44
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.3¢ | 0.2¢ | $16.54K | 5.758M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 96791453 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 58594028 | 16 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| AVE (ASX) Chart |